![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
ADAM10 is a potential biomarker for Alzheimer's disease (AD). ADAM10 protein levels are reduced in platelets of AD patients. The aim was to verify the total blood and platelet ADAM10 gene expression in AD patients and to compare with mild cognitive impairment (MCI) and healthy subjects. No significant differences in ADAM10 gene expression were observed. Therefore, the decrease of ADAM10 protein in platelets of AD patients is not caused by a reduction in ADAM10 mRNA. Further studies must be performed to investigate other pathways in the down regulation of ADAM10 protein.
Acknowledgements
The authors thank all the subjects and their families.
Declaration of interest
All the authors declare no conflict of interest.
The authors are grateful for the financial support of FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo, grant #2010/09497-7 and 2013/06879-4). P.R. Manzine has a scholarship sponsored by FAPESP (grant #2012/08654-7). E. Marcello had a fellowship sponsored by the Italian Society of Pharmacology.
Supplementary material available online
Supplementary Figures 1 and 2